Latest Intelgenx Technologs (IGXT) Headlines
IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines
GlobeNewswire - Mon Mar 03, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, that they submitted a response to the Complete Response Letter ("CRL") of the U.S. Food and Drug Administration ("FDA") for the New Drug Application ("NDA") for their VersaFilm(TM) Oral Film Product for the treatment of acute migraines.
RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film
GlobeNewswire - Mon Mar 03, 7:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, today announced, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, that they submitted a response to the Complete Response Letter ("CRL") of the U.S. Food and Drug Administration ("FDA") for the New Drug Application ("NDA") for RHB-103, an oral thin-film rizatriptan for the treatment of acute migraines.
IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related to Proprietary Technology
GlobeNewswire - Wed Feb 26, 7:42AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, today announced that it has received a Notice of Allowance ("NOA") from the United States Patent and Trademark Office for U.S. Patent Application Serial No. 11/647,033 entitled "Multilayer tablet" which covers the technology used in our hypertension product currently under development. A second NOA has been received for U.S. Patent Application Serial No. 11/782,838 entitled "Controlled-release pharmaceutical tablets" which is related to the drug delivery technology used in Forfivo XL(R), IntelGenx' first FDA-approved product currently commercialized in the U.S. These two NOA's conclude the examination of each U.S. patent application and will result in the issuance of two U.S. patents after administrative processes are completed.
IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm(TM) Tadalafil Product
GlobeNewswire - Mon Feb 24, 7:08AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, today announced the completion of a pilot biostudy with its proprietary VersaFilm(TM) tadalafil product for erectile dysfunction that indicated bioequivalence with the leading brand reference listed drug (RLD) tadalafil product.
IntelGenx Technologies Report Delivers Analyst Opinion and Fundamental Data
PR Newswire - Wed Feb 05, 6:00AM CST
NEW YORK, Feb. 5, 2014 /PRNewswire - IntelGenx Technologies Corp (OTC: IGXT), is a drug delivery company, that engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market.
IntelGenx and RedHill Biopharma Receive Complete Response Letter From FDA for VersaFilm(TM) Oral Film Product for Acute Migraines
GlobeNewswire - Tue Feb 04, 9:49PM CST
-- FDA's letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies; IntelGenx and RedHill plan to address remaining issues, primarily related to third party manufacturing, packaging and labeling, within weeks based on available data
11th Trust Dialogue - Impunity Number One Enemy of Democracy-Ekeweremadu
by Ronald Mutum - All Africa Global Media - Fri Jan 17, 1:21AM CST
The Deputy Senate President, Ike Ekeweremadu has said impunity in politics is the number one enemy of Nigeria's democracy.
IntelGenx Announces Additional Development and Commercialization Agreement With Par Pharmaceutical, Inc. for Two More Products
GlobeNewswire - Mon Jan 13, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" or the "Company"), a Canadian drug delivery company focusing on oral drug delivery, today announced that it has entered into another development and commercialization agreement with Par Pharmaceutical, Inc. ("Par") for two new products utilizing IntelGenx' proprietary oral drug delivery platforms.
IntelGenx Grants Stock Options
GlobeNewswire - Thu Jan 09, 10:34AM CST
IntelGenx Technologies Corp. ("IntelGenx", or the "Company") (TSX-V:IGX) (OTCQX:IGXT) announced today that the Company's board of directors granted options to acquire 120,000 common shares under the 2006 Stock Option Plan, as amended. The options were granted to the President and Chief Executive Officer, Dr. Rajiv Khosla in accordance with his employment agreement.
IntelGenx Closes $3.5 Million Public Offering
GlobeNewswire - Mon Dec 16, 2:35PM CST
IntelGenx Technologies Corp. (OTCQX:IGXT) (TSX-V:IGX) ("IntelGenx"), a drug delivery company focused on the development of novel oral rapidly disintegrating delivery systems including its proprietary VersaFilm(TM) technology, as well as oral controlled-release products, announced today that it has closed a registered public offering to raise gross proceeds of approximately $3.5 million.
IntelGenx Announces Public Offering of $3,500,000 of Common Stock
GlobeNewswire - Thu Dec 12, 7:05AM CST
IntelGenx Technologies Corp. (OTCQX:IGXT) (TSX-V:IGX) ("IntelGenx"), a drug delivery company focused on the development of novel oral rapidly disintegrating delivery systems including its proprietary VersaFilm(TM) technology, as well as oral controlled-release products, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $3.5 million of securities in a registered public offering. IntelGenx has agreed to sell to institutional investors an aggregate of 7,920,346 shares of its common stock at $0.4419 per share. Additionally, investors will receive warrants to purchase up to 7,920,346 shares of common stock at an exercise price of $0.5646 per share for a term of five years.
Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013
M2 - Fri Nov 22, 3:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/l62htg/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013" report to their offering. 'Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure). Scope - A snapshot of the global therapeutic scenario for Congestive Heart Failure (Heart Failure). - A review of the Congestive Heart Failure (Heart Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Congestive Heart Failure (Heart Failure) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Aastrom Biosciences, Inc. Johnson & Johnson Amgen Inc. AstraZeneca PLC Athersys, Inc. GlaxoSmithKline plc Gilead Sciences, Inc. Merck & Co., Inc. Bioheart, Inc. Neurocrine Biosciences, Inc. Novartis AG Acorda Therapeutics, Inc. Dong-A Pharmaceutical Co., Ltd. Les Laboratoires Servier Bayer AG Celladon Corporation IntelGenx Technologies Corp. Mesoblast Ltd Palatin Technologies, Inc. Cardio3 BioSciences SA La Jolla Pharmaceutical Company and many more... For more information visit http://www.researchandmarkets.com/research/l6...tive_heart About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IntelGenx Reports Q3, 2013 Results and Corporate Development Highlights
GlobeNewswire - Fri Nov 08, 5:05AM CST
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx") today announced financial results for the three and nine months ended September 30, 2013 and provided an update on operational developments. All amounts are in U.S. dollars, unless otherwise stated.
Cancer Pain - Pipeline Review, H2 2013
M2 - Wed Oct 09, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k9j8kq/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2013" report to their offering. 'Cancer Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cancer Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Pain. Scope - A snapshot of the global therapeutic scenario for Cancer Pain. - A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cancer Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cancer Pain. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Kyowa Hakko Kirin Co., Ltd. Amgen Inc. BioDelivery Sciences International, Inc. Daiichi Sankyo Company, Ltd Sangamo BioSciences, Inc. Egalet a/s Alexza Pharmaceuticals, Inc. Samyang Corporation Aphios Corporation AcelRx Pharmaceuticals, Inc. Laboratoires Pierre Fabre SA Nippon Kayaku Co., Ltd. Nippon Shinyaku Co., Ltd. Orion Corporation Pfizer Inc. Zeria Pharmaceutical Co Ltd GW Pharmaceuticals plc IntelGenx Technologies Corp. and many more... For more information visit http://www.researchandmarkets.com/research/k9...ancer_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines
GlobeNewswire - Mon Mar 03, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, that they submitted a response to the Complete Response Letter ("CRL") of the U.S. Food and Drug Administration ("FDA") for the New Drug Application ("NDA") for their VersaFilm(TM) Oral Film Product for the treatment of acute migraines.
RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film
GlobeNewswire - Mon Mar 03, 7:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, today announced, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, that they submitted a response to the Complete Response Letter ("CRL") of the U.S. Food and Drug Administration ("FDA") for the New Drug Application ("NDA") for RHB-103, an oral thin-film rizatriptan for the treatment of acute migraines.
IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related to Proprietary Technology
GlobeNewswire - Wed Feb 26, 7:42AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, today announced that it has received a Notice of Allowance ("NOA") from the United States Patent and Trademark Office for U.S. Patent Application Serial No. 11/647,033 entitled "Multilayer tablet" which covers the technology used in our hypertension product currently under development. A second NOA has been received for U.S. Patent Application Serial No. 11/782,838 entitled "Controlled-release pharmaceutical tablets" which is related to the drug delivery technology used in Forfivo XL(R), IntelGenx' first FDA-approved product currently commercialized in the U.S. These two NOA's conclude the examination of each U.S. patent application and will result in the issuance of two U.S. patents after administrative processes are completed.
IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm(TM) Tadalafil Product
GlobeNewswire - Mon Feb 24, 7:08AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"), a Canadian drug delivery company focusing on oral drug delivery, today announced the completion of a pilot biostudy with its proprietary VersaFilm(TM) tadalafil product for erectile dysfunction that indicated bioequivalence with the leading brand reference listed drug (RLD) tadalafil product.
IntelGenx Technologies Report Delivers Analyst Opinion and Fundamental Data
PR Newswire - Wed Feb 05, 6:00AM CST
NEW YORK, Feb. 5, 2014 /PRNewswire - IntelGenx Technologies Corp (OTC: IGXT), is a drug delivery company, that engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market.
IntelGenx and RedHill Biopharma Receive Complete Response Letter From FDA for VersaFilm(TM) Oral Film Product for Acute Migraines
GlobeNewswire - Tue Feb 04, 9:49PM CST
-- FDA's letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies; IntelGenx and RedHill plan to address remaining issues, primarily related to third party manufacturing, packaging and labeling, within weeks based on available data
11th Trust Dialogue - Impunity Number One Enemy of Democracy-Ekeweremadu
by Ronald Mutum - All Africa Global Media - Fri Jan 17, 1:21AM CST
The Deputy Senate President, Ike Ekeweremadu has said impunity in politics is the number one enemy of Nigeria's democracy.
IntelGenx Announces Additional Development and Commercialization Agreement With Par Pharmaceutical, Inc. for Two More Products
GlobeNewswire - Mon Jan 13, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" or the "Company"), a Canadian drug delivery company focusing on oral drug delivery, today announced that it has entered into another development and commercialization agreement with Par Pharmaceutical, Inc. ("Par") for two new products utilizing IntelGenx' proprietary oral drug delivery platforms.
IntelGenx Grants Stock Options
GlobeNewswire - Thu Jan 09, 10:34AM CST
IntelGenx Technologies Corp. ("IntelGenx", or the "Company") (TSX-V:IGX) (OTCQX:IGXT) announced today that the Company's board of directors granted options to acquire 120,000 common shares under the 2006 Stock Option Plan, as amended. The options were granted to the President and Chief Executive Officer, Dr. Rajiv Khosla in accordance with his employment agreement.
IntelGenx Closes $3.5 Million Public Offering
GlobeNewswire - Mon Dec 16, 2:35PM CST
IntelGenx Technologies Corp. (OTCQX:IGXT) (TSX-V:IGX) ("IntelGenx"), a drug delivery company focused on the development of novel oral rapidly disintegrating delivery systems including its proprietary VersaFilm(TM) technology, as well as oral controlled-release products, announced today that it has closed a registered public offering to raise gross proceeds of approximately $3.5 million.
IntelGenx Announces Public Offering of $3,500,000 of Common Stock
GlobeNewswire - Thu Dec 12, 7:05AM CST
IntelGenx Technologies Corp. (OTCQX:IGXT) (TSX-V:IGX) ("IntelGenx"), a drug delivery company focused on the development of novel oral rapidly disintegrating delivery systems including its proprietary VersaFilm(TM) technology, as well as oral controlled-release products, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $3.5 million of securities in a registered public offering. IntelGenx has agreed to sell to institutional investors an aggregate of 7,920,346 shares of its common stock at $0.4419 per share. Additionally, investors will receive warrants to purchase up to 7,920,346 shares of common stock at an exercise price of $0.5646 per share for a term of five years.
Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013
M2 - Fri Nov 22, 3:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/l62htg/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013" report to their offering. 'Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure). Scope - A snapshot of the global therapeutic scenario for Congestive Heart Failure (Heart Failure). - A review of the Congestive Heart Failure (Heart Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Congestive Heart Failure (Heart Failure) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Aastrom Biosciences, Inc. Johnson & Johnson Amgen Inc. AstraZeneca PLC Athersys, Inc. GlaxoSmithKline plc Gilead Sciences, Inc. Merck & Co., Inc. Bioheart, Inc. Neurocrine Biosciences, Inc. Novartis AG Acorda Therapeutics, Inc. Dong-A Pharmaceutical Co., Ltd. Les Laboratoires Servier Bayer AG Celladon Corporation IntelGenx Technologies Corp. Mesoblast Ltd Palatin Technologies, Inc. Cardio3 BioSciences SA La Jolla Pharmaceutical Company and many more... For more information visit http://www.researchandmarkets.com/research/l6...tive_heart About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IntelGenx Reports Q3, 2013 Results and Corporate Development Highlights
GlobeNewswire - Fri Nov 08, 5:05AM CST
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx") today announced financial results for the three and nine months ended September 30, 2013 and provided an update on operational developments. All amounts are in U.S. dollars, unless otherwise stated.
Cancer Pain - Pipeline Review, H2 2013
M2 - Wed Oct 09, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k9j8kq/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2013" report to their offering. 'Cancer Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cancer Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Pain. Scope - A snapshot of the global therapeutic scenario for Cancer Pain. - A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cancer Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cancer Pain. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Kyowa Hakko Kirin Co., Ltd. Amgen Inc. BioDelivery Sciences International, Inc. Daiichi Sankyo Company, Ltd Sangamo BioSciences, Inc. Egalet a/s Alexza Pharmaceuticals, Inc. Samyang Corporation Aphios Corporation AcelRx Pharmaceuticals, Inc. Laboratoires Pierre Fabre SA Nippon Kayaku Co., Ltd. Nippon Shinyaku Co., Ltd. Orion Corporation Pfizer Inc. Zeria Pharmaceutical Co Ltd GW Pharmaceuticals plc IntelGenx Technologies Corp. and many more... For more information visit http://www.researchandmarkets.com/research/k9...ancer_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
